ASCO 2026 highlights breast cancer care: gene tests help skip chemo, new SERDs and ADCs improve outcomes, ctDNA guides ...

Five-year OS was 94.4% with ALND omission vs 93.4% with completion ALND (HR 0.89), confirming non-inferiority; breast cancer–specific survival was similarly high in both arms. Inclusion of mastectomy ...

Breakthrough research presented at the 2026 Society of Thoracic Surgeons Annual Meeting shows that additional lymph node evaluation is needed during surgery for non-small cell lung cancer (NSCLC) to ...

We sought to evaluate whether patients with breast cancer who undergo a total mastectomy (TM) can safely forgo a completion axillary lymph node dissection (cALND) in the presence of one to three ...

Removing more lymph nodes in the pelvis probably results in fewer deaths from bladder cancer, but may make no difference to death from any cause or the cancer coming back (all measured within five ...

Background and objectives: After neoadjuvant chemotherapy (NACT), the likelihood of loco-regional recurrence (LRR) within 10 years in locally-advanced breast cancer patients (cT1–3, N0–N1) is ...

Following propensity score matching, the comparative results between the two groups remained statistically non-significant. The five-year axillary recurrence-free survival (ARFS) rate was 99.2% for ...

Dr. Ko Un “Clara” Park and Dr. Mylin Torres present the latest evidence-based changes to the SLNB in early-stage breast cancer guideline. They discuss the practice-changing trials that led to the ...

A study has shown that lymph node transfer is a viable treatment for the swelling in the affected limb, a condition known as lymphedema, after breast cancer surgery. However, an effective drug to ...